Acambis shares soar on $548M buyout deal

Shares of Acambis soared after Sanofi Pasteur, the vaccine division of Sanofi-Aventis, announced that it planned to buy the vaccine developer for $548 million. Aside from the smallpox vaccine ACAM2000, which recently won a 10-year, $425 million contract from the U.S. government, Sanofi-Aventis also gains a slate of experimental vaccines for dengue fever, West Nile disease and clostridium difficile, influenza and genital herpes.

Sanofi Pasteur and Acambis are partnered on a variety of development programs already. And the deal underscores just how attractive vaccine companies have become. Sanofi-Aventis "quite liked what we had in Acambis," said Acambis Chief Executive Ian Garland.

- check out Sanofi's release
- read the Wall Street Journal report
- here's the AP story

Related Articles:
Acambis contract offers long-term funding
Out with old, in with new smallpox vaccine
Universal flu vaccine shows early promise
Acambis takes aim at proof-of-concept vaccine trial
Sanofi buys into Acambis' West Nile vaccine program